An Open-Label, Phase 2b Global Multicenter Cohort Trial of Zipalertinib in Locally Advanced or Metastatic NSCLC with Exon 20 Insertion and Uncommon/Single or Compound EGFR Mutations
September 11, 2026
A Phase 1/2a, Open-Label Study of SA53-OS, an MDM2 Inhibitor, in Locally Advanced or Metastatic p53 Wild-Type Solid Tumors